The correlation between PSMA expression levels and treatment response in prostate cancer underscores the pivotal role of PET-PSMA imaging in stratifying patients based on their risk profile and guiding personalized treatment approaches. This evidence concerns the gene FOLH1 and Familial prostate cancer.